Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares
- 27 August 2014
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (4), 497-503
- https://doi.org/10.1111/1756-185x.12422
Abstract
To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it ≥ 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the ≥ 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.Keywords
This publication has 25 references indexed in Scilit:
- Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008Arthritis & Rheumatism, 2011
- Frequency and risk factors of gout flares in a large population-based cohort of incident goutRheumatology, 2011
- Hyperuricemia and incident hypertension: A systematic review and meta‐analysisArthritis Care & Research, 2010
- Patients and providers view gout differently: a qualitative studyChronic Illness, 2010
- Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005Annals Of The Rheumatic Diseases, 2007
- Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendationsAnnals Of The Rheumatic Diseases, 2007
- British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of GoutRheumatology, 2007
- Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination SurveyArthritis Care & Research, 2007
- EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)Annals Of The Rheumatic Diseases, 2006
- Preliminary criteria for the classification of the acute arthritis of primary goutArthritis & Rheumatism, 1977